Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

FDA Warns of Neurological Risks with Epidural Corticosteroid Injections for Pain; ASA Collaborating with Medical Organizations to Develop Recommendations on Safe Use of Epidural Steroid Injections

Friday, April 25, 2014


On April 23, the U.S. Food and Drug Administration (FDA), in a change long-expected by the medical community, issued a Safety Announcement warning that “injection of corticosteroids into the epidural space of the spine may result in rare but serious adverse events, including loss of vision, stroke, paralysis, and death.”  As a result, the FDA is requiring the addition of a warning to injectable corticosteroids’ drug labels to describe these risks.  The FDA recommends that “Patients should discuss the benefits and risks of epidural corticosteroid injections with their health care professionals, along with the benefits and risks associated with other possible treatments.”

The FDA unilaterally issued this warning as ASA and other national medical organizations, in a Work Group facilitated by the FDA’s Safe Use Initiative, finalize a comprehensive set of evidence-based recommendations aimed at using current scientific knowledge to guide practitioners about how to perform epidural steroid injections in the safest possible way to minimize the risk of patient injury.  These recommendations were presented at a special panel during the ANESTHESIOLOGY™ 2013 annual meeting, at which presenters concluded that:

• There is an increased chance of neurologic injury when particulate steroids are used for transforaminal injections. 

• There is an increased chance of neurologic injury with transforaminal epidural approach compared to the interlaminar approach. 

• Use of image-guidance is mandatory when performing transforaminal injections.

The practice recommendations will be published in the peer-reviewed literature and this information will be widely disseminated to all practitioners with the help of the FDA’s Safe Use Initiative.  

ASA will continue to work with the FDA and stakeholders to discuss the benefits of epidural steroid injections and to reduce preventable harm.


Read the FDA’s Safety Announcement.

Learn about the FDA’s Safe Use Initiative Project on Epidural Steroid Injections.



« Back to Washington Alerts